20 minute delayed
Join Market Matters and get full access to all our Opinion + Action
Fairly valued
Morningstar Quantitative Rating as of 28 OCT 2026.
Quantitative Equity Rating Methodology – view here
Five-star price 2.16 Fair value 2.63 One-star price 3.19
Morningstar Quantitative Rating as of 28 OCT 2026.
Morningstar Quantitative Rating as of 28 OCT 2026. The slider runs from the five-star price (2.16) to the one-star price (3.19).
| Ratios |
|---|
| Currency (Price/reporting): AUD/AUD |
| Exchange Rate: 1.0000 |
| Price - closing or last bid | 2.72 |
| Price - 12 month high | 3.20 |
| Price - 12 month low | 2.47 |
| Pricing date | 28 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 21.16 |
| Market capitalization | 31,398.87 |
| 12 Month High price date | 26 FEB 2026 |
| 12 Month Low price date | 18 SEP 2026 |
| Volume - avg. trading volume for the last 3 months | 18.16 |
| Price - 1 Day % Change | 0.00% |
| Price - 13 week price percent change | -6.21% |
| Price - 26 week price percent change | -1.09% |
| Price - 5 Day % Change | -1.09% |
| Price - 52 week price percent change | -11.97% |
| Price - YTD price percent change | -7.48% |
| Price % Change Month To Date | 6.25% |
| EPS excluding extraordinary items - most recent fiscal year | 0.062 |
| EPS excluding extraordinary items - trailing 12 month | 0.062 |
| EPS Normalized - most recent fiscal year | 0.064 |
| Revenue/share - most recent fiscal year | 0.942 |
| Revenue/share - trailing 12 month | 0.942 |
| Book value per share - most recent fiscal year | 0.434 |
| Book value per share - most recent half-year | 0.434 |
| Book value (tangible) per share - most recent fiscal year | 0.099 |
| Book value (tangible) per share - most recent half-year | 0.099 |
| Cash per share - most recent fiscal year | 0.011 |
| Cash per share - most recent half-year | 0.011 |
| Cash Flow per share - most recent fiscal year | 0.050 |
| Cash Flow per share - trailing 12 month | 0.050 |
| Dividend per share - most recent fiscal year | — |
| Dividends per share - trailing 12 month | 0.040 |
| EBITD per share - trailing 12 month | 0.099 |
| EPS Basic excluding extraordinary items - most recent fiscal year | 0.062 |
| EPS Basic excluding extraordinary items - trailing 12 month | 0.062 |
| EPS including extraordinary items - most recent fiscal year | 0.062 |
| EPS including extraordinary items - trailing 12 month | 0.062 |
| Free Cash Flow per share - trailing 12 month | 0.045 |
| P/E excluding extraordinary items, most recent fiscal year | 43.87 |
| P/E Normalized, most recent fiscal year | 42.72 |
| Price to sales - most recent fiscal year | 2.89 |
| Price to Tangible Book - most fiscal year | 27.34 |
| Price to Free Cash Flow per Share - most recent fiscal year | 60.41 |
| Price to Cash Flow per share - trailing 12 month | 54.44 |
| Price to Book - most recent fiscal year | 6.26 |
| P/E excluding extraordinary items high, trailing 12 months | 61.96 |
| P/E excluding extraordinary items low, trailing 12 months | 40.32 |
| Net Debt, LFI | 1,839.40 |
| Net Debt, LFY | 1,889.42 |
| Dividend Yield - 5 Year Average | 0.72% |
| Dividend Yield - indicated annual dividend divided by closing price | 1.47% |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 1.47% |
| Free Cash Flow - most recent fiscal year | 517.91 |
| LT debt/equity - most recent fiscal year | 36.33% |
| Payout ratio - most recent fiscal year | — |
| Total debt/total equity - most recent fiscal year | 40.50% |
| LT debt/equity - most recent half-year | 36.84% |
| Total debt/total equity - most recent half-year | 40.95% |
| Free Cash Flow - trailing 12 month | 517.91 |
| Payout ratio - trailing 12 month | — |
| Revenue - most recent fiscal year | 10,834.97 |
| Revenue - trailing 12 month | 10,834.97 |
| EBITD - most recent fiscal year | 1,141.94 |
| EBITD - trailing 12 month | 1,141.94 |
| Earnings before taxes - most recent fiscal year | 1,005.07 |
| Earnings before taxes - trailing 12 month | 1,005.07 |
| Net Income available to common - most recent fiscal year | 709.18 |
| Net Income available to common - trailing 12 months | 709.18 |
| Earnings before taxes Normalized - most recent fiscal year | 1,018.12 |
| Net Income Available to Common, Normalized - most recent fiscal year | 732.30 |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | 0.06 |
| Net Profit Margin % - 1st historical fiscal year | 6.54% |
| Net Profit Margin % - trailing 12 month | 6.54% |
| Operating margin - 1st historical fiscal year | 9.16% |
| Operating margin - trailing 12 month | 9.16% |
| Pretax margin - trailing 12 month | 9.28% |
| Pretax margin - 1st historical fiscal year | 9.28% |
| Operating Margin - 5 year average | — |
| Pretax Margin - 5 year average | — |
| Free Operating Cash Flow/Revenue, 5 Year Average | — |
| Free Operating Cash Flow/Revenue, TTM | 4.78% |
| Net Profit Margin - 5 year average | — |
| Return on average assets - most recent fiscal year | 8.20% |
| Return on average assets - trailing 12 month | 8.20% |
| Return on average equity - most recent fiscal year | 14.60% |
| Return on average equity - trailing 12 month | 14.60% |
| Return on average assets - 5 year average | — |
| Return on average equity - 5 year average | — |
| Net Income/employee - most recent fiscal year | — |
| Revenue/employee - most recent fiscal year | — |
| Revenue growth rate, 5 year | — |
| EPS growth rate, 5 year | — |
| Growth rate% - dividend, 3 year | — |
| Revenue/share (5 yr growth) | — |
| Growth rate% - Revenue, 3 year | — |
| Growth rate% - EPS, 3 year | — |
| Book value per share growth rate, 5 year | — |
| Capital Spending growth rate, 5 year | — |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | — |
Financial forecast (AUD, millions except per share)
| Actuals | Estimates | |||||||
| 2026 | 2027 | 2028 | 2029 | 2030 | ||||
| Estimate breakdown | ||||||||
Financials (AUD, millions)
| Period end: | JUN 25 | JUN 26 |
| Fiscal year: | 2025 | 2026 |
| Period length: | 12 months | 12 months |
Announcements
| DATE | TIME | HEADING | PAGES |
| Price sensitive |
SIG -7.75%: Was sold off despite another year of strong headline growth, with the market focusing on revenue falling short of consensus following the transformational Chemist Warehouse combination. Australian Chemist Warehouse like-for-like sales remain impressive and management expects double-digit revenue and earnings growth in 1H27, but expectations around this business are high.
SIG -0.66%: First-half half results were out from the pharmaceutical goods wholesaler today, coming in broadly in line with expectations though there were positive signs on the cost front. Revenue for the half was $1.68b, down -8.4% on the back of lower RAT sales and following the sale of their Hospital supply arm.
SIG -5.71%: first half results from the pharmaceutical product wholesaler was reasonable on the first read, however there are still a number of issues holding performance back. EBITDA was up 17% to $20.7m, while the company posted a net loss of $1.5m, though it included $38.7m worth of write-downs on assets and inventory. RAT sales continued to prop up the numbers, though a return to ‘normal’ has...
SIG +1.92%: Sigma is a chemist retailer operating under brands like Amcal and they also have a large wholesale business, although smaller than it once was after losing the contract to supply Chemist Warehouse a few years ago. They released FY22 results today and presented to us this afternoon. We haven’t really looked at SIG before and find it hard to get excited about the stock right now, although it is in turnaround mode. Today’s result was...
SIG -2%: surprisingly tough finish to the day for Sigma who substantially upgraded guidance for their FY22 result due out at the end of the month. The pharmaceutical wholesaler upgraded EBITDA guidance to 10-15% growth for the year against previous guidance of +10% as strong demand for COVID RATs helped turnaround performance into the January year end. Despite the big shift in guidance, the result...
SIG +1.68%: the pharmaceutical wholesaler re-joined the running to take out Priceline owner Australian Pharmaceutical Industries (API) today in a battle that’s now spanned 3 years. Wesfarmers had thrown a bid in for API only a few months ago at $1.55/sh cash, in a deal that looked all but wrapped up before Sigma’s moves today. They have offered 2.05 shares...
MM is neutral toward SIG
MM is neutral toward SIG
MM is neutral SIG
MM is neutral/negative SIG ~66c
MM has no real interest in SIG
MM is not excited about SIG ~50c
Sigma Healthcare is Australia's largest retail pharmacy franchisor, most notably owning the Chemist Warehouse brand, which it merged with in 2025. Sigma is also Australia's largest full-line wholesaler to franchised and independent pharmacies and distributes a broad range of pharmacy products, including prescription medicines, over-the-counter products, and front of store, or FOS, products, at low prices. The group also operates in New Zealand, Ireland, China, and Dubai, hasa growing private label range, and offers third-party logistics services.
Forgot password? Request a One Time Password or reset your password
One Time Password
Check your email for an email from [email protected]
Subject: Your OTP for Account Access
This email will have a code you can use as your One Time Password for instant access
A link to create a new password will be sent to the email address you have registered to your account.
Hi, this is only available to members. Join today and access the latest views on the latest developments from a professional money manager.
Our Smart Phone App will give you access to much of our content and notifications. Download for free today.
Hi, this is only available to members. Join today and access the latest views on the latest developments from a professional money manager.
JOIN NOW
Something went wrong. Please try again in a moment.
